Lexicon Pharmaceuticals (NASDAQ:LXRX) Issues Earnings Results, Beats Estimates By $0.03 EPS

Lexicon Pharmaceuticals (NASDAQ:LXRX) issued its quarterly earnings data on Thursday. The biopharmaceutical company reported ($0.04) EPS for the quarter, topping analysts’ consensus estimates of ($0.07) by $0.03, FiscalAI reports. Lexicon Pharmaceuticals had a negative return on equity of 40.53% and a negative net margin of 101.08%.The firm had revenue of $5.49 million during the quarter, compared to the consensus estimate of $3.14 million.

Here are the key takeaways from Lexicon Pharmaceuticals’ conference call:

• SONATA?HCM (sotagliflozin) has surpassed 50% enrollment across 130+ sites and is on track to complete enrollment by mid?2026 with top?line results expected in Q1?2027, representing a potential first?in?class HCM opportunity.
• Management expects to resubmit the NDA for Zynquista in type 1 diabetes in 2026 based on the investigator?led Steno?1 study, with a ~6?month review and potential approval later in 2026 if patient exposure and DKA rates meet FDA criteria.
• Pilavapadin received a successful end?of?Phase?2 meeting with the FDA (no objections to Phase?3 design) and Lexicon is actively seeking a development partner for pivotal studies rather than self?funding Phase 3.
• Early obesity program LX9851 triggered a $10M milestone from Novo Nordisk, development has been handed off to Novo, and up to $20M more in milestones are possible in 2026, signaling partner validation of the asset.
• Financially, operating expenses and net loss improved materially in 2025 and Lexicon raised >$100M of additional cash post?year?end, but year?end cash was $125.2M and 2026 operating expense guidance is $100–110M, indicating ongoing financing and execution needs.

Lexicon Pharmaceuticals Stock Up 4.3%

Lexicon Pharmaceuticals stock opened at $1.71 on Friday. Lexicon Pharmaceuticals has a 52 week low of $0.32 and a 52 week high of $1.83. The stock has a market cap of $621.53 million, a price-to-earnings ratio of -12.21 and a beta of 0.94. The company’s 50-day moving average price is $1.36 and its two-hundred day moving average price is $1.33. The company has a current ratio of 5.64, a quick ratio of 5.63 and a debt-to-equity ratio of 0.47.

Analyst Ratings Changes

LXRX has been the subject of several recent research reports. Weiss Ratings restated a “sell (d-)” rating on shares of Lexicon Pharmaceuticals in a research report on Thursday, January 22nd. Wall Street Zen downgraded shares of Lexicon Pharmaceuticals from a “buy” rating to a “hold” rating in a research report on Saturday, November 15th. Finally, HC Wainwright boosted their target price on shares of Lexicon Pharmaceuticals from $4.00 to $6.00 and gave the company a “buy” rating in a research note on Thursday. Two analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the stock. According to MarketBeat.com, Lexicon Pharmaceuticals presently has an average rating of “Hold” and an average price target of $3.95.

Insider Buying and Selling

In related news, Director Raymond Debbane acquired 100,000 shares of the firm’s stock in a transaction dated Monday, February 23rd. The stock was acquired at an average cost of $1.47 per share, for a total transaction of $147,000.00. Following the completion of the acquisition, the director directly owned 1,904,186 shares of the company’s stock, valued at approximately $2,799,153.42. The trade was a 5.54% increase in their position. The transaction was disclosed in a filing with the SEC, which is available through the SEC website. Also, Director Invus Global Management, Llc bought 1,538,462 shares of the company’s stock in a transaction that occurred on Monday, February 2nd. The shares were purchased at an average cost of $1.30 per share, for a total transaction of $2,000,000.60. Following the acquisition, the director owned 1,538,462 shares of the company’s stock, valued at $2,000,000.60. This represents a ? increase in their ownership of the stock. The disclosure for this purchase is available in the SEC filing. Over the last ninety days, insiders bought 1,790,462 shares of company stock valued at $2,369,981. Company insiders own 13.90% of the company’s stock.

Institutional Trading of Lexicon Pharmaceuticals

A number of large investors have recently added to or reduced their stakes in the business. Security National Bank of Sioux City Iowa IA acquired a new position in Lexicon Pharmaceuticals in the fourth quarter worth approximately $31,000. Hudson Bay Capital Management LP acquired a new stake in shares of Lexicon Pharmaceuticals during the 2nd quarter valued at $26,000. EntryPoint Capital LLC bought a new stake in shares of Lexicon Pharmaceuticals during the 4th quarter worth $39,000. Virtu Financial LLC bought a new stake in shares of Lexicon Pharmaceuticals during the 4th quarter worth $42,000. Finally, CIBC Asset Management Inc acquired a new position in shares of Lexicon Pharmaceuticals in the 4th quarter worth $45,000. 74.70% of the stock is currently owned by institutional investors.

Key Stories Impacting Lexicon Pharmaceuticals

Here are the key news stories impacting Lexicon Pharmaceuticals this week:

• Positive Sentiment: Q4 results beat expectations — GAAP EPS of -$0.04 vs. -$0.07 consensus and revenue of $5.49M vs. $3.14M expected, which relieved near-term execution concerns and likely helped the stock. Earnings beat summary
• Positive Sentiment: Clinical progress: management confirmed sotagliflozin pivotal milestones are on schedule (including planned NDA resubmission in T1D and enrollment of the SONATA HCM study) and reported a positive End?of?Phase?2 meeting with the FDA for pilavapadin, supporting Phase 3 readiness. These program updates materially de?risk future value drivers. Press release with clinical updates
• Positive Sentiment: Balance-sheet boost — management disclosed more than $100M in additional cash from a capital raise plus a Novo Nordisk milestone payment, improving runway and reducing near?term financing risk. Press release with financing detail
• Positive Sentiment: Analyst upgrade / price-target raise — H.C. Wainwright reiterated a Buy rating and raised its target to $6, signaling bullish analyst conviction and providing a large implied upside that can attract momentum buyers. Analyst note / PT raise
• Neutral Sentiment: Management hosted an earnings call and published slides/transcript; these provide more detail for investors but are informational rather than catalytic. Earnings call transcript
• Negative Sentiment: Company remains unprofitable with a negative net margin (~96.8%) and negative return on equity; consensus still forecast a full?year loss (current consensus ~ -$0.66 EPS), so fundamentals remain challenged absent clinical or commercial validation. Earnings / metrics summary
• Negative Sentiment: Biotech execution and regulatory risk persist — upcoming clinical readouts and the NDA resubmission are binary events that could reverse gains if outcomes disappoint. Clinical & regulatory update

About Lexicon Pharmaceuticals

Lexicon Pharmaceuticals, Inc is a biopharmaceutical company focused on the discovery and development of novel medicines through its proprietary genome biology platform. By leveraging large-scale gene knockout libraries, the company identifies potential therapeutic targets and advances them through preclinical and clinical development. Lexicon’s approach emphasizes the translation of genetic insights into targeted therapies for a range of human diseases.

The company’s most advanced product is telotristat ethyl (sold under the brand name XERMELO), an oral treatment approved for the management of carcinoid syndrome diarrhea in patients inadequately controlled by somatostatin analog therapy.